Skip to content

Study · Not a test of the peptide alone · 2008

8 results

Cutting edge: vasoactive intestinal peptide (VIP) induces differentiation of Th17 cells with a distinctive cytokine profile.

Yadav M, Rosenbaum J, Goetzl EJ

Journal of immunology (Baltimore, Md. : 1950)1 Mar 2008Cited by 42 (Europe PMC)

PMID18292497 (opens in a new tab)DOI10.4049/jimmunol.180.5.2772 (opens in a new tab)PepBankPUB-18292497
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    In CD4 T cells, VIP together with TGFbeta stimulated transformation to a distinctive type of Th17 cell that generates IL-17.

    In plain wordsIn lab tests, VIP together with TGFbeta turned T cells into a distinct type of Th17 cell that makes IL-17.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseIL-17 production by VIP plus TGFbeta induced Th17 cells
    Study

    mousen: not reported in source

    CD4 T cell differentiation cultures
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    VIP with TGFbeta stimulates the transformation of CD4 T cells to a distinctive type of Th17 cell that generates IL-17

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    In CD4 T cells, Th17 cells induced by VIP together with TGFbeta did not generate IL-6 or IL-21.

    In plain wordsIn lab tests, Th17 cells made with VIP plus TGFbeta did not make IL-6 or IL-21.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeIL-6 and IL-21 production by VIP plus TGFbeta induced Th17 cells
    Study

    mousen: not reported in source

    CD4 T cell differentiation cultures
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    VIP with TGFbeta stimulates the transformation of CD4 T cells to a distinctive type of Th17 cell that generates IL-17 but not IL-6 or IL-21.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    VIP-induced Th17 induction was higher in VPAC2 knockout mice than in wild-type mice, which suggests VPAC1 is the principal transducer.

    In plain wordsIn mouse cells, VIP made more Th17 cells when VPAC2 was missing, suggesting VPAC1 does most of the signaling.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableTh17 induction in VPAC2 knockout versus wild-type mice
    Study

    mousen: not reported in source

    CD4 T cell differentiation cultures
    Comparator
    Wild-type mice
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    VIP induction of Th17 cells was higher in VPAC2 knockout mice than wild-type mice, suggesting that VPAC1 is the principal transducer.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  4. 04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    Th17 cells evoked by VIP were similar to Th17 cells elicited by IL-6 in IL-17 secretion.

    In plain wordsIn lab tests, VIP-induced Th17 cells made about as much IL-17 as IL-6-induced Th17 cells.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeIL-17 secretion versus IL-6-elicited Th17 cells
    Study

    mousen: not reported in source

    CD4 T cell differentiation cultures
    Comparator
    Th17 cells elicited by IL-6
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Compared with Th17 cells elicited by IL-6, those evoked by VIP were similar in the secretion of IL-17
    1 context sentence
    Summary · context
    Compared with Th17 cells elicited by IL-6, those evoked by VIP

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  5. 05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    Th17 cells evoked by VIP were similar to Th17 cells elicited by IL-6 in IL-22 secretion.

    In plain wordsIn lab tests, VIP-induced Th17 cells made about as much IL-22 as IL-6-induced Th17 cells.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeIL-22 secretion versus IL-6-elicited Th17 cells
    Study

    mousen: not reported in source

    CD4 T cell differentiation cultures
    Comparator
    Th17 cells elicited by IL-6
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Compared with Th17 cells elicited by IL-6, those evoked by VIP were similar in the secretion of IL-17 and IL-22, but lacked IL-21 secretion.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  6. 06LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    Th17 cells evoked by VIP lacked IL-21 secretion compared with Th17 cells elicited by IL-6.

    In plain wordsIn lab tests, VIP-induced Th17 cells did not make IL-21, unlike IL-6-induced Th17 cells.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseIL-21 secretion versus IL-6-elicited Th17 cells
    Study

    mousen: not reported in source

    CD4 T cell differentiation cultures
    Comparator
    Th17 cells elicited by IL-6
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Compared with Th17 cells elicited by IL-6, those evoked by VIP were similar in the secretion of IL-17 and IL-22, but lacked IL-21 secretion.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  7. 07LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    Protein kinase A inhibitors suppressed VIP induction of Th17 cells.

    In plain wordsIn lab tests, blocking the enzyme PKA reduced Th17 cell formation by VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseEffect of protein kinase A inhibitors on VIP-induced Th17 cells
    Study

    mousen: not reported in source

    CD4 T cell differentiation cultures
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Suppression of VIP induction of Th17 cells by protein kinase A inhibitors

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  8. 08LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    Pharmacologically increased cAMP enhanced VIP induction of Th17 cells.

    In plain wordsIn lab tests, raising cAMP, a cell signal, increased Th17 cell formation by VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseEffect of increased cAMP on VIP-induced Th17 cells
    Study

    mousen: not reported in source

    CD4 T cell differentiation cultures
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    enhancement by pharmacologically increased cAMP supports a role for this signal.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.